|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
|
31823054 |
2020 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults.
|
31194593 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy.
|
30032410 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Polysorbate 80-free intravenous neurokinin-1 receptor antagonist may provide a safer chemotherapy-induced nausea and vomiting prophylaxis option.
|
30301373 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The plasma concentrations of 5-HT in Group T was lower than Group C at T<sub>1</sub> (348.54 ± 138.49 vs. 418.69 ± 124.68, P = 0.03), T<sub>2</sub> (324.28 ± 112.73 vs. 398.52 ± 114.53, P < 0.01), T<sub>4</sub> (309.64 ± 129.09 vs. 388.46 ± 115.36, P = 0.04) postoperatively and concentrations of SP at T<sub>1</sub> (59.38 ± 24.68 vs. 78.93 ± 26.32, P < 0.01), T<sub>2</sub> (49.36 ± 25.55 vs. 66.49 ± 23.57, P = 0.02), T<sub>3</sub> (42.19 ± 24.36 vs. 64.15 ± 28.16, P = 0.04), T<sub>4</sub> (39.26 ± 19.88 vs. 54.64 ± 20.62, P = 0.02) postoperatively were also lower than Group C. Meanwhile, the occurrences of vertigo (6.7 vs. 18.3%, P < 0.01), nausea and vomiting (11.7 vs. 21.7%, P < 0.01), constipation (10.0 vs. 20.0%, P = 0.03) in Group T were also lower.
|
29557487 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As a combination of a neurokinin-1 (NK<sub>1</sub>) receptor antagonist (RA) and 5-HT<sub>3</sub>RA, NEPA offers 5-day chemotherapy-induced nausea and vomiting prevention with a single dose and an opportunity to improve adherence to antiemetic guidelines.
|
31801902 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
|
30304952 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rolapitant (Varubi) is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced nausea and vomiting.
|
30422319 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for prevention of delayed chemotherapy-induced nausea and vomiting in adults.
|
30624856 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
|
30426714 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with dexamethasone and a 5-hydroxytryptamine type 3 receptor antagonist for the prevention of delayed chemotherapy-induced nausea and vomiting in adults.
|
29905976 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Rolapitant is a neurokinin-1 receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed chemotherapy-induced nausea and vomiting.
|
30084103 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chemotherapy-induced nausea and vomiting are concerning adverse events resulting from cancer treatment, and current guidelines recommend the use of neurokinin-1-selective antagonists, such as fosaprepitant, in highly emetogenic schemes.
|
30870506 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting.
|
30733446 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HTX-019 [CINVANTI<sup>®</sup> (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting.
|
30706408 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The current randomized, double-blind, phase 2 study assessed the efficacy and safety profile of a single intravenous administration of fosnetupitant, a neurokinin 1 receptor antagonist prodrug, for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving cisplatin-based chemotherapy.
|
31381152 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Netupitant/palonosetron (NEPA) is a fixed combination of serotonin-3 (5-HT<sub>3</sub>) and neurokinin-1 (NK<sub>1</sub>) receptor antagonists (RAs), respectively, indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
|
31094589 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Oral (aprepitant, 2003; netupitant, 2014; rolapitant, 2015) neurokinin-1 receptor antagonists have been developed along with intravenous formulations (fosaprepitant, NEPA, rolapitant, HTX-019) for the prevention of chemotherapy-induced nausea and vomiting.<b>Areas covered</b>: This review presents a description of the safety and efficacy of rolapitant along with a comparison to the other oral and intravenous formulations of the neurokinin-1 receptor antagonists.<b>Expert opinion</b>: Oral rolapitant has been demonstrated in clinical trials to be safe and effective in controlling chemotherapy-induced nausea and vomiting in patients receiving moderately and highly emetogenic chemotherapy.
|
31622113 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy.
|
30576544 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.
|
30709557 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
More recently a small proof of concept study has suggest that aprepitant, an NK-1 antagonist licensed for the prevention of chemotherapy induced nausea and vomiting, might have beneficial effects on cough frequency in patients with lung cancer.
|
31622673 |
2019 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.
|
30323622 |
2018 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aprepitant (APT), an antiemetic drug belonging to the class of substance P antagonists is efficiently used in both acute and delayed chemotherapy-induced nausea and vomiting.
|
29880085 |
2018 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
|
29130344 |
2018 |
|
Nausea and vomiting
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis.
|
29548482 |
2018 |